The invention relates to a sodium salt of uric acid transporter inhibitor and its crystalline form. In particular, the invention relates to a sodium salt of uric acid transporter (URAT1) inhibitor, its type I crystallization and a preparation method thereof. The invention relates to sodium 1 - (6-bromoquinoline-4-yl) thio) cyclobutylcarboxylate (compound of formula (I)), its type I crystallization and a preparation method thereof. The type I crystal of the compound of formula (I) has good crystal stability and chemical stability, and the crystal solvent used has low toxicity and low residue, which can be better used in clinical treatment.本發明涉及一種尿酸轉運蛋白抑制劑的鈉鹽及其結晶形式。具體而言，本發明涉及一種尿酸轉運蛋白(URAT1)抑制劑的鈉鹽、其I型結晶及製備方法。本發明涉及1‑((6‑溴喹啉‑4‑基)硫基)環丁基甲酸鈉(式(I)化合物)、其I型結晶及其製備方法。本發明所得到式(I)化合物的I型結晶具備良好的晶型穩定性和化學穩定性，並且所用結晶溶劑低毒低殘留，可更好地用於臨床治療。
